Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...

Valerie is a seasoned writer and editor who has spent her career creating content in the parenting and women's wellness spaces. Before joining Forbes Health, Valerie was the trending news editor at ...